- Home
- FIG vs JAZZ Comparison
FIG vs JAZZ Comparison
Compare FIG & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | JAZZ |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 10.4B |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FIG | JAZZ |
|---|---|---|
| Price | $22.87 | $166.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $55.22 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 13.2M | 774.0K |
| Earning Date | 02-18-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $968,957,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $40.99 | $6.19 |
| Revenue Next Year | $23.11 | $6.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 91.92 | 4.14 |
| 52 Week Low | $19.85 | $95.49 |
| 52 Week High | $142.92 | $182.99 |
Technical Indicators
Market Signals| Indicator | FIG | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 50.01 |
| Support Level | $21.15 | $161.38 |
| Resistance Level | $25.17 | $167.73 |
| Average True Range (ATR) | 1.93 | 4.02 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 29.01 | 58.07 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.